Sheena Bhalla is an Oncology physician affiliated with The University of Texas Southwestern Medical Center. OpenAlex indexes 51 publications with 2,403 citations (h-index 14); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6201 Harry Hines Blvd
Dallas, TX 753905204
Telephone
214-633-5555Provider last certified this registry record 1 Sept 2021.
Clinical trials
- Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC
Sponsor: University of Texas Southwestern Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- EMD Serono, Inc.Program year20253 payments
- Janssen Biotech, Inc.Program year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
24.2%Kinase inhibitor24.2%Tagrisso100%Part D<11 patientsBlood & clotting
16.1%Factor Xa inhibitor16.1%Eliquis100%Part D<11 patientsMetabolism & gastrointestinal
15.7%Corticosteroid9.9%Prednisone100%Part D≥11 patientsSerotonin-3 Receptor Antagonist5.8%Ondansetron Hcl100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Innate and adaptive immune features associated with immune-related adverse events
Journal for ImmunoTherapy of Cancer
2025 - Virtual Health Care Encounters for Lung Cancer Screening in a Safety-Net Population: Observations From the COVID-19 Pandemic
JCO Clinical Cancer Informatics
2025 - Radiologists’ Perceptions of the 21st Century Cures Act
Journal of the American College of Radiology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Toto, MD
The University of Texas Southwestern Medical Center
Margaret Pearle, MD, PhD
The University of Texas Southwestern Medical Center
George Buchanan, MD
The University of Texas Southwestern Medical Center
Vitaly Margulis, MD
The University of Texas Southwestern Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”